[144] Abbott Laboratories SEC Filing
Abbott Laboratories (ABT) filed a Form 144 proposing the sale of 5,550 shares of common stock. The notice states the shares have an aggregate market value of $746,758.27 and lists total outstanding shares of 1,740,459,014. The proposed sale is to be executed through UBS Financial Services on the NYSE with an approximate sale date of 08/08/2025.
The filing shows all 5,550 shares were acquired by the filer as vested restricted stock awards on 02/28/2022 (1,801 shares), 02/28/2023 (3,559 shares), and 02/29/2024 (190 shares). The form reports "Nothing to Report" for securities sold in the past three months and includes the standard signature representation about absence of undisclosed material adverse information.
Abbott Laboratories (ABT) ha presentato un Modulo 144 proponendo la vendita di 5,550 azioni ordinarie. La comunicazione indica che le azioni hanno un valore di mercato complessivo di $746,758.27 e riporta un totale di azioni in circolazione di 1,740,459,014. La vendita proposta sar脿 eseguita tramite UBS Financial Services sul NYSE con data approssimativa di vendita 08/08/2025.
La documentazione mostra che tutte le 5,550 azioni sono state acquisite dal dichiarante come restricted stock award maturate il 02/28/2022 (1,801 azioni), 02/28/2023 (3,559 azioni) e 02/29/2024 (190 azioni). Il modulo riporta "Niente da segnalare" per titoli venduti negli ultimi tre mesi e include la consueta dichiarazione firmata relativa all'assenza di informazioni materiali avverse non divulgate.
Abbott Laboratories (ABT) present贸 un Formulario 144 proponiendo la venta de 5,550 acciones ordinarias. El aviso indica que las acciones tienen un valor de mercado agregado de $746,758.27 y lista un total de acciones en circulaci贸n de 1,740,459,014. La venta propuesta se ejecutar谩 a trav茅s de UBS Financial Services en la NYSE con una fecha aproximada de venta de 08/08/2025.
La presentaci贸n muestra que las 5,550 acciones fueron adquiridas por el declarante como premios de acciones restringidas adquiridas (vested restricted stock awards) el 02/28/2022 (1,801 acciones), 02/28/2023 (3,559 acciones) y 02/29/2024 (190 acciones). El formulario informa "Nada que informar" respecto a valores vendidos en los 煤ltimos tres meses e incluye la representaci贸n de firma est谩ndar sobre la ausencia de informaci贸n adversa material no divulgada.
Abbott Laboratories (ABT)電� 氤错喌欤� 5,550欤� 毵り皝鞚� 鞝滌晥頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 韱奠靹滌棎電� 頃措嫻 欤检嫕鞚� 齑� 鞁滌灔臧�旃橁皜 $746,758.27鞚措澕瓿� 旮办灛霅橃柎 鞛堨溂氅�, 齑� 氚滍枆欤检嫕靾橂姅 1,740,459,014搿� 雮橃檧 鞛堨姷雼堧嫟. 鞝滌晥霅� 毵り皝鞚� UBS Financial Services毳� 韱淀暣 NYSE鞐愳劀 鞚措（鞏挫 鞓堨爼鞚措┌, 鞓堨爼 毵り皝鞚检潃 08/08/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
靹滊鞐� 霐半ゴ氅� 5,550欤� 鞝勲秬電� 鞁犼碃鞚胳澊 頇曥爼霅� 鞝滍暅欤检嫕 靾橃棳(vested restricted stock awards)搿� 旆摑頃� 瓴冹溂搿� 雮橅儉雮橂┌, 旆摑鞚检潃 02/28/2022 (1,801欤�), 02/28/2023 (3,559欤�), 02/29/2024 (190欤�)鞛呺媹雼�. 頃措嫻 鞏戩嫕鞐愲姅 歆�雮� 靹� 雼� 霃欖晥 毵り皝霅� 歃濌秾鞐� 雽�頃� "氤搓碃頃� 雮挫毄 鞐嗢潓"鞚措澕瓿� 旮办灛霅橃柎 鞛堦碃, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頃橂姅 響滌 靹滊獏 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Abbott Laboratories (ABT) a d茅pos茅 un formulaire 144 proposant la vente de 5 550 actions ordinaires. L'avis indique que les actions ont une valeur de march茅 globale de $746,758.27 et 茅num猫re un total d'actions en circulation de 1,740,459,014. La vente propos茅e doit 锚tre ex茅cut茅e par UBS Financial Services 脿 la NYSE avec une date de vente approximative le 08/08/2025.
Le d茅p么t montre que les 5 550 actions ont toutes 茅t茅 acquises par le d茅clarant en tant qu'attributions d'actions restreintes acquises (vested restricted stock awards) le 02/28/2022 (1,801 actions), 02/28/2023 (3,559 actions) et 02/29/2024 (190 actions). Le formulaire indique "Rien 脿 d茅clarer" pour les titres vendus au cours des trois derniers mois et inclut la repr茅sentation standard sign茅e concernant l'absence d'informations d茅favorables importantes non divulgu茅es.
Abbott Laboratories (ABT) hat ein Formular 144 eingereicht, das den Verkauf von 5.550 Stammaktien vorschl盲gt. Die Mitteilung gibt an, dass die Aktien einen gesamten Marktwert von $746,758.27 haben und f眉hrt die insgesamt ausstehenden Aktien mit 1,740,459,014 auf. Der vorgeschlagene Verkauf soll 眉ber UBS Financial Services an der NYSE ausgef眉hrt werden, mit einem ungef盲hren Verkaufstermin am 08/08/2025.
Die Einreichung zeigt, dass alle 5.550 Aktien vom Meldenden als voll erworbene eingeschr盲nkte Aktienzuteilungen (vested restricted stock awards) erworben wurden am 02/28/2022 (1,801 Aktien), 02/28/2023 (3,559 Aktien) und 02/29/2024 (190 Aktien). Das Formular vermerkt f眉r in den letzten drei Monaten verkaufte Wertpapiere "Nichts zu berichten" und enth盲lt die 眉bliche Unterschriftsdarstellung 眉ber das Fehlen nicht offengelegter wesentlicher nachteiliger Informationen.
- None.
- None.
Insights
TL;DR: Small, routine Form 144 filing showing proposed sale of vested restricted shares through a broker on the NYSE.
The filing documents a proposed sale of 5,550 common shares valued at $746,758.27, to be executed via UBS on 08/08/2025. The shares were acquired through vested restricted stock awards on three separate dates. There are no reported sales in the past three months. For investors, this filing is a disclosure of an insider-origin sale but contains no operational or financial performance information about the issuer.
TL;DR: Administrative disclosure of insider sale under Rule 144; reflects compensation vesting and planned market sale via a broker.
The notice identifies the nature of acquisition as Restricted Stock Award Vested with specific grant dates and quantities, and specifies the broker and exchange for the planned disposition. The form includes the required representation that the seller is not aware of undisclosed material adverse information. This is a compliance-driven filing rather than a corporate-governance event altering control or strategy.
Abbott Laboratories (ABT) ha presentato un Modulo 144 proponendo la vendita di 5,550 azioni ordinarie. La comunicazione indica che le azioni hanno un valore di mercato complessivo di $746,758.27 e riporta un totale di azioni in circolazione di 1,740,459,014. La vendita proposta sar脿 eseguita tramite UBS Financial Services sul NYSE con data approssimativa di vendita 08/08/2025.
La documentazione mostra che tutte le 5,550 azioni sono state acquisite dal dichiarante come restricted stock award maturate il 02/28/2022 (1,801 azioni), 02/28/2023 (3,559 azioni) e 02/29/2024 (190 azioni). Il modulo riporta "Niente da segnalare" per titoli venduti negli ultimi tre mesi e include la consueta dichiarazione firmata relativa all'assenza di informazioni materiali avverse non divulgate.
Abbott Laboratories (ABT) present贸 un Formulario 144 proponiendo la venta de 5,550 acciones ordinarias. El aviso indica que las acciones tienen un valor de mercado agregado de $746,758.27 y lista un total de acciones en circulaci贸n de 1,740,459,014. La venta propuesta se ejecutar谩 a trav茅s de UBS Financial Services en la NYSE con una fecha aproximada de venta de 08/08/2025.
La presentaci贸n muestra que las 5,550 acciones fueron adquiridas por el declarante como premios de acciones restringidas adquiridas (vested restricted stock awards) el 02/28/2022 (1,801 acciones), 02/28/2023 (3,559 acciones) y 02/29/2024 (190 acciones). El formulario informa "Nada que informar" respecto a valores vendidos en los 煤ltimos tres meses e incluye la representaci贸n de firma est谩ndar sobre la ausencia de informaci贸n adversa material no divulgada.
Abbott Laboratories (ABT)電� 氤错喌欤� 5,550欤� 毵り皝鞚� 鞝滌晥頃橂姅 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 韱奠靹滌棎電� 頃措嫻 欤检嫕鞚� 齑� 鞁滌灔臧�旃橁皜 $746,758.27鞚措澕瓿� 旮办灛霅橃柎 鞛堨溂氅�, 齑� 氚滍枆欤检嫕靾橂姅 1,740,459,014搿� 雮橃檧 鞛堨姷雼堧嫟. 鞝滌晥霅� 毵り皝鞚� UBS Financial Services毳� 韱淀暣 NYSE鞐愳劀 鞚措（鞏挫 鞓堨爼鞚措┌, 鞓堨爼 毵り皝鞚检潃 08/08/2025搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
靹滊鞐� 霐半ゴ氅� 5,550欤� 鞝勲秬電� 鞁犼碃鞚胳澊 頇曥爼霅� 鞝滍暅欤检嫕 靾橃棳(vested restricted stock awards)搿� 旆摑頃� 瓴冹溂搿� 雮橅儉雮橂┌, 旆摑鞚检潃 02/28/2022 (1,801欤�), 02/28/2023 (3,559欤�), 02/29/2024 (190欤�)鞛呺媹雼�. 頃措嫻 鞏戩嫕鞐愲姅 歆�雮� 靹� 雼� 霃欖晥 毵り皝霅� 歃濌秾鞐� 雽�頃� "氤搓碃頃� 雮挫毄 鞐嗢潓"鞚措澕瓿� 旮办灛霅橃柎 鞛堦碃, 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 頇曥澑頃橂姅 響滌 靹滊獏 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Abbott Laboratories (ABT) a d茅pos茅 un formulaire 144 proposant la vente de 5 550 actions ordinaires. L'avis indique que les actions ont une valeur de march茅 globale de $746,758.27 et 茅num猫re un total d'actions en circulation de 1,740,459,014. La vente propos茅e doit 锚tre ex茅cut茅e par UBS Financial Services 脿 la NYSE avec une date de vente approximative le 08/08/2025.
Le d茅p么t montre que les 5 550 actions ont toutes 茅t茅 acquises par le d茅clarant en tant qu'attributions d'actions restreintes acquises (vested restricted stock awards) le 02/28/2022 (1,801 actions), 02/28/2023 (3,559 actions) et 02/29/2024 (190 actions). Le formulaire indique "Rien 脿 d茅clarer" pour les titres vendus au cours des trois derniers mois et inclut la repr茅sentation standard sign茅e concernant l'absence d'informations d茅favorables importantes non divulgu茅es.
Abbott Laboratories (ABT) hat ein Formular 144 eingereicht, das den Verkauf von 5.550 Stammaktien vorschl盲gt. Die Mitteilung gibt an, dass die Aktien einen gesamten Marktwert von $746,758.27 haben und f眉hrt die insgesamt ausstehenden Aktien mit 1,740,459,014 auf. Der vorgeschlagene Verkauf soll 眉ber UBS Financial Services an der NYSE ausgef眉hrt werden, mit einem ungef盲hren Verkaufstermin am 08/08/2025.
Die Einreichung zeigt, dass alle 5.550 Aktien vom Meldenden als voll erworbene eingeschr盲nkte Aktienzuteilungen (vested restricted stock awards) erworben wurden am 02/28/2022 (1,801 Aktien), 02/28/2023 (3,559 Aktien) und 02/29/2024 (190 Aktien). Das Formular vermerkt f眉r in den letzten drei Monaten verkaufte Wertpapiere "Nichts zu berichten" und enth盲lt die 眉bliche Unterschriftsdarstellung 眉ber das Fehlen nicht offengelegter wesentlicher nachteiliger Informationen.
